We validated the efficacy of the CXCR1/2-targeted pepducin, x1/2pal-i3, to attenuate CXCL-mediated tumourigenicity in PTEN-modulated prostate cancer cells, using an appropriate non-targeting peptide as the relevant control. This evidence concerns the gene CXCR1 and prostate cancer.